Achieve Life Sciences (ACHV) EBT Margin (2011 - 2012)
Achieve Life Sciences (ACHV) recorded quarterly EBT Margin of 388.7% in Q4 2012, down 533.35% on a QoQ basis from 89.7% in Q3 2012, and up 125938.0% year-over-year from N/an in Q1 2012.
Achieve Life Sciences (ACHV) EBT Margin (2011 - 2012) Analysis & Trends
Achieve Life Sciences has disclosed EBT Margin across 2 years of filings, most recently posting 388.7% for Q4 2012.
- Quarterly EBT Margin rose 125938.0% year-over-year to 388.7% in Q4 2012, while the trailing twelve-month figure through Dec 2012 was 173.22% (changed N/A YoY) and the FY2012 annual result came in at 104.97%, up 16182.0% from the prior year.
- EBT Margin declined to 388.7% in Q4 2012, from 89.7% in the prior quarter.
- Over five years, EBT Margin peaked at 343.68% in Q2 2011 and troughed at 1648.08% in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -388.70% |
| Sep 30, 2012 | 89.70% |
| Jun 30, 2012 | 175.63% |
| Mar 31, 2012 | -527.69% |
| Dec 31, 2011 | -1,648.08% |
| Sep 30, 2011 | -372.50% |
| Jun 30, 2011 | 343.68% |